Trump admin moves to roll back testosterone restrictions
The federal government is rolling back nearly decade-old restrictions on testosterone replacement therapy for older men, citing new research showing reduced cardiovascular risks.
The Department of Health and Human Services announced Thursday that it is seeking updates to prescribing information for testosterone replacement therapy drugs, commonly known as TRT, according to New York Post. The move aims to ease access restrictions imposed on older men, though some medical experts warn that the existing research may not justify such broad policy changes.
In 2015, the Food and Drug Administration imposed warning labels on testosterone medications, alerting patients and doctors that the treatments had not been proven safe for low testosterone levels and could potentially trigger heart attacks or strokes. Those restrictions are now being unwound.
Government Cites New Research on Heart Risks
HHS officials point to recent studies suggesting the hormone poses far less cardiovascular danger than previously believed. The agency dropped cardiovascular warnings in 2025 and is now pushing to soften alerts concerning prostate cancer and prostate enlargement.
Robert F. Kennedy Jr., HHS Secretary, framed the policy shift as a victory for evidence-based medicine. During Men’s Health Month, we are putting science back at the center of men’s healthcare, Kennedy stated in an official press release. He said the updated labels would provide patients and physicians with clearer information while supporting informed medical decisions for millions of American men.
What TRT Treats and Who Needs It
Testosterone replacement therapy requires a prescription and is used to treat hypogonadism, a condition in which the testicles fail to produce sufficient sex hormones, primarily testosterone. The treatment can improve sex drive, enhance physical performance, increase muscle mass, reduce body fat, and stabilize energy levels and mood.
Medical research indicates that testosterone levels begin declining naturally around age 35. Approximately 35 percent of men over age 45 have hypogonadism. Obesity compounds the problem—excess body fat reduces testosterone levels, while low testosterone makes weight loss more difficult. Between 30 and 50 percent of men with obesity or type 2 diabetes suffer from hypogonadism.
Mixed Evidence on Cardiovascular Safety
The 2015 warnings stemmed from concerns about heart risks and what HHS described as limited evidence of therapeutic benefits. But the department now cites more recent research, particularly the 2023 TRAVERSE trial, which examined more than 5,200 men at high risk for heart disease who also exhibited symptoms of hypogonadism.
Researchers found that testosterone therapy caused roughly the same number of major cardiac events—including heart attacks, strokes, and deaths—as a placebo. However, men using TRT showed higher rates of atrial fibrillation, an irregular heartbeat that elevates stroke and heart failure risk, as well as pulmonary embolism, a dangerous blood clot in the lung arteries.
The study authors concluded that the cardiovascular effects of testosterone replacement in middle-aged and older hypogonadal men have not been fully determined. While some medical experts now consider testosterone safe, others maintain that additional research is necessary.
Based on the TRAVERSE study and other unspecified available evidence, the FDA has concluded that the previous limitation on use is no longer warranted. Dr. Brian J. Christine, Assistant Secretary for Health, said prescribing information should reflect the best available science as understanding of testosterone therapy continues to evolve.
Prostate Cancer Warnings Also Being Revised
Current labels on testosterone warn that men with prostate cancer or suspected prostate cancer should not use the therapy. Research shows that existing cancer can grow and multiply with TRT exposure. The labels also caution that testosterone could increase the risk of developing prostate cancer.
HHS is now proposing that use be restricted only for patients with metastatic prostate cancer—cancer that has spread to other parts of the body. Experts contend that TRT does not increase prostate cancer risk in men who do not already have the disease.
The department acknowledged that important uncertainties remain because prostate cancer can take years to develop. The proposed labeling will continue to recommend that healthcare providers assess risk, screen patients before treatment, and monitor them during therapy.
The FDA is also requesting updates to labeling related to benign prostatic hyperplasia, a noncancerous enlargement of the prostate. Current labels state that TRT could worsen the condition. The agency is asking manufacturers to change labels to recommend continued monitoring of patients with severe symptomatic disease during treatment.
FDA findings indicate that TRT does not worsen symptoms in men with mild to moderate benign prostatic hyperplasia, though the therapy’s effects remain unclear for men with severe symptoms.
Dr. Michael Davis, acting director of the FDA’s Center for Drug Evaluation and Research, said the agency’s responsibility is to ensure prescribing information reflects the best available scientific evidence.
With information from New York Post
